Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions

Cytokine and Growth Factor Reviews

Volumn 24, Issue 5, 2013, Pages 433-442

  Sun, Zhongjie ^a,b   Lei, Han ^b   Zhang, Zhonge ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

B lymphocyte; Chemokine; Monocyte; Pre B cell enhancing factor; T lymphocyte

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN; TOLL LIKE RECEPTOR;

ACUTE LUNG INJURY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATORY DISEASE; KIDNEY DISEASE; LEUKOCYTE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PBEF GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION;

B LYMPHOCYTE; CHEMOKINE; MONOCYTE; PRE-B CELL ENHANCING FACTOR; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; T-LYMPHOCYTES;

EID: 84884714145     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.05.006     Document Type: Review

References (107)

1. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology 1994, 14:1431-1437.
2. Rongvaux A., Shea R.J., Mulks M.H., et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. European Journal of Immunology 2002, 32:3225-3234.
3. Revollo J.R., Grimm A.A., Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Current Opinion in Gastroenterology 2007, 23:164-170.
4. Ognjanovic S., Ku T.L., Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. American Journal of Obstetrics and Gynecology 2005, 193:273-282.
5. Moschen A.R., Kaser A., Enrich B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 2007, 178:1748-1758.
6. Revollo J.R., Korner A., Mills K.F., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism 2007, 6:363-375.
7. Ognjanovic S., Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. American Journal of Obstetrics and Gynecology 2002, 187:1051-1058.
8. Tanaka M., Nozaki M., Fukuhara A., et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochemical and Biophysical Research Communications 2007, 359:194-201.
9. Koczan D., Guthke R., Thiesen H.J., et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. European Journal of Dermatology 2005, 15:251-257.
10. Nowell M.A., Richards P.J., Fielding C.A., et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism 2006, 54:2084-2095.
11. Dahl T.B., Yndestad A., Skjelland M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
12. Ye S.Q., Zhang L.Q., Adyshev D., et al. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvascular Research 2005, 70:142-151.
13. Ognjanovic S., Tashima L.S., Bryant-Greenwood G.D. The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis. American Journal of Obstetrics and Gynecology 2003, 189:1187-1195.
14. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
15. Fukuhara A., Matsuda M., Nishizawa M., et al. Retraction. Science 2007, 318:565.
16. Garten A., Petzold S., Korner A., Imai S., Kiess W Nampt: linking NAD biology, metabolism and cancer. Trends in Endocrinology & Metabolism 2009, 20(3):130-138.
17. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. Journal of Molecular Endocrinology 2001, 26:107-117.
18. Martin P.R., Shea R.J., Mulks M.H. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. Journal of Bacteriology 2001, 183:1168-1174.
19. Kitani T., Okuno S., Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Letters 2003, 544:74-78.
20. McGlothlin J.R., Gao L., Lavoie T., et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochemical Genetics 2005, 43:127-141.
21. Bae S.K., Kim S.R., Kim J.G., et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Letters 2006, 580:4105-4113.
22. Wang T., Zhang X., Bheda P., Revollo J.R., Imai S., Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nature Structural & Molecular Biology 2006, 13:661-662.
23. Kim M.K., Lee J.H., Kim H., et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. Journal of Molecular Biology 2006, 362:66-77.
24. Chen H., Xia T., Zhou L., et al. Gene organization, alternate splicing and expression pattern of porcine visfatin gene. Domestic Animal Endocrinology 2007, 32:235-245.
25. Kralisch S., Klein J., Lossner U., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. Journal of Endocrinology 2005, 185:R1-R8.
26. MacLaren R., Cui W., Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes, Obesity and Metabolism 2007, 9:490-497.
27. Kralisch S., Klein J., Lossner U., et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. American Journal of Physiology. Endocrinology and Metabolism 2005, 289:E586-E590.
28. Segawa K., Fukuhara A., Hosogai N., et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochemical and Biophysical Research Communications 2006, 349:875-882.
29. Chu C.H., Lee J.K., Wang M.C., et al. Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism. Metabolism: Clinical and Experimental 2008, 57:1380-1383.
30. Hector J., Schwarzloh B., Goehring J., et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Hormone and Metabolic Research 2007, 39:250-255.
31. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 2004, 92:347-355.
32. Song H.K., Lee M.H., Kim B.K., et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. American Journal of Physiology. Renal Physiology 2008, 295:F1485-F1494.
33. Liu P., Li H., Cepeda J., et al. Critical role of PBEF expression in pulmonary cell inflammation and permeability. Cell Biology International 2009, 33:19-30.
34. Krzysik-Walker S.M., Ocon-Grove O.M., Maddineni S.R., Hendricks G.L., Ramachandran R. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 2008, 149:1543-1550.
35. Kim S.R., Bae S.K., Choi K.S., et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochemical and Biophysical Research Communications 2007, 357:150-156.
36. Xie H., Tang S.Y., Luo X.H., et al. Insulin-like effects of visfatin on human osteoblasts. Calcified Tissue International 2007, 80:201-210.
37. Adya R., Tan B.K., Punn A., Chen J., Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular Research 2008, 78:356-365.
38. Kim S.R., Bae Y.H., Bae S.K., et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochimica et Biophysica Acta 2008, 1783:886-895.
39. Jia S.H., Li Y., Parodo J., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation 2004, 113:1318-1327.
40. Li Y., Zhang Y., Dorweiler B., et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. Journal of Biological Chemistry 2008, 283:34833-34843.
41. Wang P., Xu T.Y., Guan Y.F., Su D.F., Fan G.R., Miao C.Y. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovascular Research 2009, 81(2):370-380.
42. Lim S.Y., Davidson S.M., Paramanathan A.J., Smith C.C., Yellon D.M., Hausenloy D.J. The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine 2008, 12:1395-1403.
43. Liu K., Li Y., Prabhu V., et al. Augmentation in expression of activation-induced genes differentiates memory from naive CD4+ T cells and is a molecular mechanism for enhanced cellular response of memory CD4+ T cells. Journal of Immunology 2001, 166:7335-7344.
44. Nau G.J., Richmond J.F., Schlesinger A., Jennings E.G., Lander E.S., Young R.A. Human macrophage activation programs induced by bacterial pathogens. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:1503-1508.
45. Feske S., Giltnane J., Dolmetsch R., Staudt L.M., Rao A. Gene regulation mediated by calcium signals in T lymphocytes. Nature Immunology 2001, 2:316-324.
46. Rongvaux A., Galli M., Denanglaire S., et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. Journal of Immunology 2008, 181:4685-4695.
47. Benson V., McMahon A.C., Lowe H.C. ICAM-1 in acute myocardial infarction: a potential therapeutic target. Current Molecular Medicine 2007, 7:219-227.
48. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annual Review of Immunology 2005, 23:487-513.
49. Jonker M., Ossevoort Ma, Vierboom M. Blocking the CD80 and CD86 costimulation molecules: lessons to be learned from animal models. Transplantation 2002, 73:S23-S26.
50. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunological Reviews 2008, 226:205-218.
51. Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. Journal of Biological Chemistry 2004, 279:50754-50763.
52. Hassa P.O., Haenni S.S., Elser M., Hottiger M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiology and Molecular Biology Reviews 2006, 70:789-829.
53. Lerner F., Niere M., Ludwig A., Ziegler M. Structural and functional characterization of human NAD kinase. Biochemical and Biophysical Research Communications 2001, 288:69-74.
54. Yang T., Sauve A.A. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS Journal 2006, 8:E632-E643.
55. Luk T., Malam Z., Marshall J.C. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. Journal of Leukocyte Biology 2008, 83:804-816.
56. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews 2007, 87:245-313.
57. Giannakou M.E., Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends in Cell Biology 2004, 14:408-412.
58. Kobayashi Y., Furukawa-Hibi Y., Chen C., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. International Journal of Molecular Medicine 2005, 16:237-243.
59. Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO Journal 2005, 24:1021-1032.
60. Luo J., Nikolaev A.Y., Imai S., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
61. Vaziri H., Dessain S.K., Ng Eaton E., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
62. Yang H., Lavu S., Sinclair D.A. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity?. Experimental Gerontology 2006, 41:718-726.
63. Ye S.Q., Simon B.A., Maloney J.P., et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. American Journal of Respiratory and Critical Care Medicine 2005, 171:361-370.
64. Zhang L.Q., Adyshev D.M., Singleton P., et al. Interactions between PBEF and oxidative stress proteins--a potential new mechanism underlying PBEF in the pathogenesis of acute lung injury. FEBS Letters 2008, 582:1802-1808.
65. Hong S.B., Huang Y., Moreno-Vinasco L., et al. Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine 2008, 178:605-617.
66. Li H., Liu P., Cepeda J., et al. Augmentation of pulmonary epithelial cell IL-8 expression and permeability by pre-B-cell colony enhancing factor. Journal of Inflammation (London) 2008, 5:15.
67. Gosset M., Berenbaum F., Salvat C., et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis and Rheumatism 2008, 58:1399-1409.
68. Brentano F., Schorr O., Ospelt C., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 2007, 56:2829-2839.
69. Otero M., Lago R., Gomez R., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006, 65:1198-1201.
70. Zhong M., Tan H.W., Gong H.P., Wang S.F., Zhang Y., Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology (Oxf). 2008, 69(6):878-884.
71. Kato A., Odamaki M., Ishida J., Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. American Journal of Nephrology 2008, 29:31-35.
72. Adya R., Tan B.K., Chen J., Randeva H.S. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis. 2009, 205(1):113-119.
73. van der Veer E., Nong Z., O'Neil C., Urquhart B., Freeman D., Pickering J.G. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circulation Research 2005, 97:25-34.
74. Chen M.P., Chung F.M., Chang D.M., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2006, 91:295-299.
75. Hallschmid M., Randeva H., Tan B.K., Kern W., Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes. 2009, 58(3):637-640.
76. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006, 49:1909-1914.
77. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. Journal of Clinical Endocrinology and Metabolism 2006, 91:1578-1581.
78. Zhang Y.Y., Gottardo L., Thompson R., et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006, 14:2119-2126.
79. Tokunaga A., Miura A., Okauchi Y., et al. The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocrine Journal 2008, 55:205-212.
80. Krzyzanowska K., Mittermayer F., Krugluger W., Kopp H.P., Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006, 14:1886-1889.
81. Krzyzanowska K., Krugluger W., Mittermayer F., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clinical Science (London) 2006, 110:605-609.
82. Lopez-Bermejo A., Chico-Julia B., Fernandez-Balsells M., et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006, 55:2871-2875.
83. Pagano C., Pilon C., Olivieri M., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology and Metabolism 2006, 91:3165-3170.
84. Garcia-Fuentes E., Garcia-Almeida J.M., Garcia-Arnes J., et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 2007, 15:2391-2395.
85. Korner A., Garten A., Bluher M., Tauscher R., Kratzsch J., Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism 2007, 92:4783-4791.
86. Axelsson J., Witasp A., Carrero J.J., et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. American Journal of Kidney Diseases 2007, 49:237-244.
87. Song H.K., Lee M.H., Kim B.K., Park Y.G., Ko G.J., Kang Y.S., et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. American Journal of Physiology. Renal Physiology 2008, 295(5):F1485-1494.
88. Tanuma S., Johnson G.S. ADP-ribosylation of nonhistone high mobility group proteins in intact cells. Journal of Biological Chemistry 1983, 258:4067-4070.
89. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
90. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology 2005, 5:331-342.
91. Sitia G., Iannacone M., Muller S., Bianchi M.E., Guidotti L.G. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. Journal of Leukocyte Biology 2007, 81:100-107.
92. van Beijnum J.R., Buurman W.A., Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99.
93. Mullins G.E., Sunden-Cullberg J., Johansson A.S., et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 2004, 60:566-573.
94. Kalinina N., Agrotis A., Antropova Y., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:2320-2325.
95. Li W., Sama A.E., Wang H. Role of HMGB1 in cardiovascular diseases. Current Opinion in Pharmacology 2006, 6:130-135.
96. Ueno H., Matsuda T., Hashimoto S., et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 2004, 170:1310-1316.
97. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annual Review of Biochemistry 2004, 73:417-435.
98. Chen J., Zhou Y., Mueller-Steiner S., et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. Journal of Biological Chemistry 2005, 280:40364-40374.
99. Benveniste E.N., Nguyen V.T., Wesemann D.R. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain, Behavior, and Immunity 2004, 18:7-12.
100. Dzielak D.J. The immune system and hypertension. Hypertension 1992, 19:I36-I44.
101. Liao T.D., Yang X.P., Liu Y.H., et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008, 52:256-263.
102. Muller D.N., Shagdarsuren E., Park J.K., et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. American Journal of Pathology 2002, 161:1679-1693.
103. Jurewicz M., McDermott D.H., Sechler J.M., et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. Journal of the American Society of Nephrology 2007, 18:1093-1102.
104. Guzik T.J., Hoch N.E., Brown K.A., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. Journal of Experimental Medicine 2007, 204:2449-2460.
105. Hoch N.E., Guzik T.J., Chen W., et al. Regulation of T-cell function by endogenously produced angiotensin II. American Journal of Physiology. Regulatory Integrative and Comparative Physiology 2009, 296:R208-R216.
106. Sheppard F.R., Kelher M.R., Moore E.E., McLaughlin N.J., Banerjee A., Silliman C.C. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. Journal of Leukocyte Biology 2005, 78:1025-1042.
107. Rodriguez-Iturbe B., Vaziri N.D., Herrera-Acosta J., Johnson R.J. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. American Journal of Physiology. Renal Physiology 2004, 286:F606-F616.